# Study of Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer

> **NCT02529878** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Zhejiang Chinese Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** S1/Paclitaxel chemotherapy plus Apatinib

## Key facts

- **NCT ID:** NCT02529878
- **Lead sponsor:** The First Affiliated Hospital of Zhejiang Chinese Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-08
- **Primary completion:** 2016-08
- **Final completion:** 2019-08
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2016-07-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02529878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02529878, "Study of Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02529878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*